Finding treatment weaknesses in synovial sarcoma cancer cells
Official title: Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma
Funded at Sloan-Kettering Inst Can Research · NIH-10848816 · Data updated 2026-11-12
This study is looking at a type of cancer called synovial sarcoma to find out how certain genetic changes might make it more vulnerable to new treatments, especially by combining special therapies that target genes with those that help the immune system fight the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2018 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $436,396 |
| NIH project number | 2P50CA217694-06A1 |
| Project ID | NIH-10848816 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with synovial sarcoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with other types of cancer or those without synovial sarcoma may not benefit from this specific research.
What this research studies
This research focuses on synovial sarcoma, a type of cancer that may have unique vulnerabilities due to specific genetic changes. The team aims to identify these vulnerabilities by studying how certain proteins and genetic modifications affect cancer cell behavior. They will explore the potential for combining epigenetic therapies with immunotherapy to improve treatment outcomes. By analyzing cancer cells and their responses to different treatments, the research seeks to develop more effective strategies for managing this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and quality of life for patients with synovial sarcoma.
How similar studies have gone: Previous research has shown promise in targeting epigenetic vulnerabilities in other cancers, suggesting potential success for this novel approach in synovial sarcoma.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Ladanyi, Marc — Sloan-Kettering Inst Can Research
- Study coordinator: Ladanyi, Marc
Related research
Other NIH-funded projects on the same topics.
-
Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma
A cancer research project at Sloan Kettering aims to find epigenetic and immune vulnerabilities in synovial sarcoma to guide future treatments.
-
Sensor-based test for synovial sarcoma that detects SS18-SSX fusion mRNA and protein
A patient-friendly test is being developed to rapidly and precisely detect the SS18-SSX cancer hallmark in synovial sarcoma using a new nanopore sensing method.
-
Finding drug and immune therapy targets for synovial sarcoma
This project looks for weaknesses in synovial sarcoma cells that new drugs or immune therapies could target for people with synovial sarcoma.
-
Targeting a specific pathway to treat synovial sarcoma
This work explores a new way to stop synovial sarcoma, a type of cancer, by disrupting a process called SUMOylation.
-
Disruption of a specific protein modification to treat synovial sarcoma
This study is exploring a new way to treat synovial sarcoma, a type of cancer that usually affects younger people, by using a special drug called TAK-981 to target a process that helps the cancer grow, with the hope of damaging the cancer cells and reducing tumors in mice.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.